We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

AI-Enhanced Platform Detects Cardiac Amyloidosis by Assessing Single Echocardiogram

By MedImaging International staff writers
Posted on 27 Apr 2023
Print article
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)

Cardiac amyloidosis, a condition resulting from abnormal protein deposits in heart tissue, is a diverse disease that can be challenging to diagnose, often necessitating specialized expertise and testing. The disease is categorized based on the specific protein involved, with the primary subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by the misfolding of the transthyretin protein, and a less common form called light chain amyloidosis (AL cardiac amyloidosis), caused by the buildup of immunoglobulin light chains. Now, an AI-powered platform can detect cardiac amyloidosis by analyzing echocardiograms and using just one commonly acquired ultrasound view of the heart.

The platform, EchoGo Amyloidosis, from Ultromics (Oxford, UK) utilizes AI technology to address the unmet need for early diagnosis of amyloidosis patients, who might otherwise remain undiagnosed until the disease has progressed, delaying treatment and negatively affecting patient outcomes. Developed in collaboration with multiple leading clinical partners, EchoGo Amyloidosis is designed as a module within Ultromics' EchoGo Platform and has received FDA Breakthrough Device Status. This FDA Breakthrough Device Designation represents a significant advancement for amyloidosis patients, who face a bleak five-year mortality rate of 44%-65% after diagnosis if the condition is not detected early enough.

"Receiving a breakthrough designation for EchoGo Amyloidosis, emphasizes the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics. "This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease. We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients."

Related Links:

Gold Supplier
Ultrasound System
Gold Supplier
Electrode Solution and Skin Prep
X-Ray Protective Head Cap
RA611 & RA612
X-Ray Generator
RF Series

Print article



view channel
Image: Intelligent NR provides high-quality diagnostic images containing significantly less grainy noise (Photo courtesy of Canon)

AI-Driven DR System Produces Higher Quality Images While Limiting Radiation Doses in Pediatric Patients

Ionizing radiation is a fundamental element in producing diagnostic X-rays, yet it's widely acknowledged for its cancer risk potential. Digital projection radiography, a vital imaging modality, accounts... Read more


view channel
Image: The researchers are using MRI-guided radiation therapy that pairs daily MRIs with radiation treatment (Photo courtesy of Sylvester)

AI Technique Automatically Traces Tumors in Large MRI Datasets to Guide Real-time Glioblastoma Treatment

Treating glioblastoma, a prevalent and aggressive brain cancer, involves the use of radiation therapy guided by CT imaging. While this method is effective in targeting radiation, it doesn't provide real-time... Read more

Nuclear Medicine

view channel
Image: A novel PET radiotracer facilitates early, noninvasive detection of IBD (Photo courtesy of Karmanos)

New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is an inflammatory condition of the gastrointestinal tract affecting roughly seven million individuals globally.... Read more

General/Advanced Imaging

view channel
Image: Artificial intelligence predicts therapy responses for ovarian cancer (Photo courtesy of 123RF)

AI Model Combines Blood Test and CT Scan Analysis to Predict Therapy Responses in Ovarian Cancer Patients

Ovarian cancer annually impacts thousands of women, with many diagnoses occurring at advanced stages due to subtle early symptoms. High-grade serous ovarian carcinoma, which accounts for 70-80% of ovarian... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Attendees can discover innovative products and technology in the RSNA 2023 Technical Exhibits (Photo courtesy of RSNA)

RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More

The 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA, Oak Brook, IL, USA) to be held in Chicago, Nov. 26 to 30 is all set to offer a vast array of medical... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.